GLP1R and metastatic malignant neoplasm: Supporting this hypothesis, the dulaglutide, another GLP-1 receptor agonist with a long half-life [159], had a trend of prophylactic effects on metastatic cancers (OR = 0.71, 95%Cis = 0.47 to 1.06 in comparison with controls) and was ranked the second in overall metastatic cancer prevention.